Carotid artery intima-media thickness and hypertensive heart disease: a short review

Costan G. Magnussen 1,2

Abstract
Sustained by its relative ease of assessment, carotid artery intima-media thickness (cIMT) has emerged as an important surrogate marker of target organ damage in hypertensive heart disease over the last three decades. However, the prognostic utility of cIMT in hypertensive heart disease differs depending on its application. This review outlines cIMT and its prognostic utility among patients with hypertensive heart disease. It provides an overview of limitations of cIMT and areas for future research.

Keywords: Hypertension, Carotid artery intima-media thickness, End organ damage, Blood pressure, Review

Background
Since the method was first proposed in the mid-1980s [1], the ultrasonic evaluation of the combined intimal and medial layers of the common carotid arteries has garnered substantial scientific and clinical support as an early, preclinical, vascular endpoint. Non-invasive, inexpensive, reproducible, and with prognostic utility among the asymptomatic and diseased, it is increasingly being used as a surrogate outcome or marker of target organ damage, or used as a tool to base treatment strategies. Although the use of carotid intima-media thickness (cIMT) is pervasive, it is not without controversy.

Measured from B-mode ultrasound images as the distance between the intima-lumen interface and the media-adventitia interface (Fig. 1), there have been substantial methodological differences among studies in their approach to determining cIMT. These differences include the artery examined (left, right, or both), arterial segments to be examined (common carotid, internal carotid, bifurcation), and the position of the measurements within these segments, the phase of the cardiac cycle, the walls (near or far), whether plaque is included in the measurement, ultrasound technology, image angle, and the approach to measurement (mean, max, or mean of the max; average across all segments; type of analysis software – semi-automated vs. manual) [2].

Different approaches to cIMT acquisition and measurement have been shown to vary in terms of reproducibility, predictive utility, rate of change, susceptibility to drug treatment, and the ability to obtain images for measurement [3]. Recent progress toward standardising approaches to image acquisition and measurement of cIMT are proving useful [4–7] but more work is required to ensure these approaches are well integrated and appropriate for different research areas and questions.

In the hypertensive patient, identification of asymptomatic target organ damage may help inform treatment decisions, and refine or reclassify an individual’s cardiovascular disease risk. cIMT is one surrogate marker of target organ damage in the hypertensive patient that is considered in guideline statements by several authorities. The following will briefly overview the utility of cIMT for the hypertensive patient.

Pathophysiology
Traditional ultrasound is unable to differentiate the intima and media as separate entities [8]. Therefore, an increased cIMT can be a result of a thicker intima, media, or both. Processes involved in intimal thickening are largely thought to mimic those in the pathogenesis and progression of atherosclerotic plaques, whereas hypertrophy of the media layer is primarily related to hypertension unrelated to atherosclerosis [7, 9]. Although thickening of the intima and media can occur by separate pathways, the elastic carotid artery has a relatively small media compared with muscular arteries and thus an...
increased cIMT is thought to largely denote intimal rather than medial thickening [10] and might explain the close association between cIMT and atherosclerotic-related cardiovascular events [11]. However, cIMT is considered a separate phenotype to atherosclerotic plaque formation and progression [7], with different clinical utility [12], and as such, should be measured in areas free of plaque [4].

**Prevalence**

Prevalence data are not readily available because there is no widely accepted cut-off for what constitutes an adverse cIMT value. However, the European Society of Hypertension (ESH)/European Society of Cardiology (ESC) guidelines for the management of hypertension suggest a value greater than 0.9 mm as being a conservative estimate of asymptomatic organ damage [13]. Before criteria for what defines an abnormal cIMT can be established, there is need for measurement consensus and population reference values. In recent years there has been a concerted effort to standardise approaches to image acquisition and analysis with one example the initiation and routine update to the Mannheim Consensus statement [4]. Moreover, recent attempts to establish cIMT reference values among diseased and healthy populations have been notable, with the most comprehensive of these using data from approximately 25,000 individuals across 14 countries [14]. Interestingly, these data showed that a cIMT value of greater than 0.9 mm advocated by the ESH/ESC equates to values above the 90th percentile among the healthy, though very few less than 70 years of age would meet this criterion level. Because of the large age and sex effect on cIMT, suggestion of race or ethnicity differences in cIMT [15–18], as well as the variability introduced by different scanning and measurement protocols, any cut-points, if they were to be established, will likely need to recognise these differences.

**Clinical and prognostic significance**

Since introduction of the technique, a plethora of data has emerged showing associations between traditional and emerging cardiovascular disease risk markers with cIMT and that cIMT associates with disease elsewhere in the vascular tree [19]. As with cardiovascular events, the association between systolic blood pressure and cIMT tends to be linear [20]. Irrespective of other risk factors, children with elevated blood pressure have higher adult cIMT than their counterparts [21], but those who are able to amend their elevated blood pressure status in the time between childhood and adulthood have a similar prevalence of high cIMT in adulthood as those that never had elevated blood pressure [22]. Clinical trials of antihypertensive medications have shown cIMT to regress or progress at a decreased rate among those...
receiving best therapy compared with those on different regimes or placebo [23–26].

There is substantial evidence that has demonstrated the utility of cIMT to predict incident vascular events in the asymptomatic [27] and diseased, including the hypertensive patient, with a 1-standard deviation increase in cIMT shown to associate with an 8% increased risk of myocardial infarction and 19% increased risk of stroke [28]. Nevertheless, the added value of cIMT measurements over and above risk factors included in the Framingham Risk Score, is inconsistent [29]. These inconsistencies, and the prevalent measurement issues, were the main weaknesses cited by the 2013 American College of Cardiology/American Heart Association guideline on the assessment of cardiovascular risk as reason not to measure cIMT [30]. Indeed, the ESH/ESC in their 2013 guidelines [31] were more cautious in their advice for cIMT measurement among hypertensive patients than in their 2007 release [13]. For hypertensive patients, the caution appears warranted following recent results from the IMPROVE (Immediate Management of the Patient with Ruptured Aneurysm: Open Versus Endovascular repair) cohort that showed area under the receiver operating curve, or c-statistic, to predict myocardial infarction and stroke was virtually unchanged when cIMT was added to the Framingham Risk Score [28]. Net reclassification improvement (NRI), which assesses the proportion of patients correctly reclassified to either a higher or lower risk, with the addition of cIMT was also low (1.4%). There has been suggestion that cIMT might benefit those of intermediate risk based on the Framingham Risk Score, and though IMPROVE found some statistical evidence of improved reclassification among hypertensive patients, the effect was again negligible (NRI = 5.6%).

Future research questions/needs
Measurement standardisation and the establishment of population norms are needed, with strong recent progress being made in these areas. Progress is also being made with respect to the clinical utility of cIMT to reclassify risk among certain groups. Though the data suggest that cIMT, if it were to be used, might be most useful for reclassifying risk status amongst those of intermediate risk of a future event, data are not available as to whether the reclassification has a measurable impact on morbidity or mortality or whether the costs associated with scanning for cIMT outweigh the associated benefits, if indeed this is shown to be the case. Clinical studies should assess whether identifying an abnormal cIMT among the hypertensive patient asymptomatic of other target organ damage would improve treatment related outcomes. Particularly among the hypertensive patient, the utility of intima-media thickness measurements from other arterial sites such as in more muscular arteries that tend to have a thicker medial layer might provide additional prognostic utility over cIMT [11]. Interest has been gathering for the potential of cIMT to be used as a surrogate outcome for intervention trials, with a positive result acting as a trigger to initiate large-scale and costly testing of these interventions with the desired outcome of morbidity and mortality [32]. The potential use of cIMT in the paediatric setting to assess and monitor target organ damage in high-risk children has been reported [3, 33–35]. However, the application of cIMT to the paediatric setting has limitations that mimics those for adult populations – namely, lack of normative values and best measurement protocols, poor understanding of which cIMT segments provide best diagnostic utility, and its cost-effectiveness for routine monitoring.

Conclusion
Measures of cIMT are elevated amongst those with hypertensive heart disease. Although individuals with a higher cIMT are at increased risk of clinical cardiovascular outcomes, the prognostic utility of cIMT differs by application and whether or not other risk factors are considered in the prediction. Further standardisation in measurement protocols, the subsequent establishment of a clear level of cIMT beyond which indicates target organ damage, and cost-effectiveness analysis of routine scanning of cIMT may provide additional information on the clinical usefulness of cIMT measurements for the hypertensive patient.

Abbreviations
cIMT: Carotid artery intima-media thickness; ESC: European society of cardiology; ESH: European society of hypertension; IMPROVE: Immediate management of the patient with ruptured aneurysm: open versus endovascular repair; NRI: Net reclassification improvement

Acknowledgements
Not applicable.

Funding
CGM is supported by a National Heart Foundation of Australian Future Leader Fellowship (100849). The funding bodies did not play a role in the study design, collection, analysis, and interpretation of data, in the writing of the manuscript, or the decision to submit the manuscript for publication.

Availability of data and material
Not applicable.

Author’s contribution
CGM compiled, wrote, and critically reviewed the manuscript.

Competing interests
The author declares he has no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Not applicable.

Received: 27 September 2016 Accepted: 3 January 2017
Published online: 02 April 2017
References

1. Piglioli P, Tremoli E, Poli A, Oreste P, Paolotti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation. 1986;74(6):1399–406.

2. Peters SA, Bots ML. Carotid intima-media thickness studies: study design and data analysis. J Stroke. 2013;15(1):38–48.

3. Bots ML, Sutton-Tyrrell K. Lessons from the past and promises for the future for carotid intima-media thickness. J Am Coll Cardiol. 2012;60(17):1599–604.

4. Touboul PJ, Hennis MG, Mears S, Adams H, Amarenco P, Bomstein N, et al. Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 15th, 18th and 20th European stroke conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2005, and Hamburg, Germany, 2011. Cerebrovasc Dis. 2012;34(4):290–6.

5. Riches NO, Alder S, White GL, Druding R, Bond MG, De Michele M. Standardized ultrasound protocol, trained sonographers and digital system for carotid atherosclerosis screening. J Cardiovasc Med (Hagerstown). 2010;11(9):683–8.

6. Polak JF, Pencina MJ. Measuring carotid artery intima-media thickness: simplicity versus complexity? J Am Soc Echocardiogr. 2011;22(5):1(101–4.

7. Stein JH, Korczak CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American society of echocardiography carotid intima-media thickness task force. Endorsed by the society for vascular medicine. J Am Soc Echocardiogr. 2008;21(2):93–111. quiz 89–90.

8. O’Leary DH, Bots ML. Imaging of atherosclerosis: carotid intima-media thickness. Eur Heart J. 2010;31(14):1682–9.

9. Roman MJ, Saba PS, Piri R, Spitzer M, Pickering TG, Rosen S, et al. Parallel cardiac and vascular adaptation in hypertension. Circulation. 1992;86(6):1909–18.

10. Grobbee DE, Bots ML. Carotid artery intima-media thickness as an indicator of generalised atherosclerosis. J Intern Med. 1994;236(5):567–73.

11. Van Bertom LM. What does intima-media thickness tell us? J Hypertens. 2005;23(13):237–9.

12. Roman MJ, Kizer JR, Best LG, Lee ET, Howard BV, Shara NM, et al. Vascular biomarkers in the prediction of cardiovascular disease: the Strong Heart Study. Hypertension. 2012;59(5):29–35.

13. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the european society of cardiology (ESC). Eur Heart J. 2007;28(12):1462–536.

14. Engelen L, Ferreira I, Stehouwer CD, Boutouyrie P, Laurent S. Reference values for carotid intima-media thickness measured with B-mode ultrasonography in asymptomatic subjects. Eur Heart J. 1993;14(9):1297–304.

15. Howard G, Sharratt AR, Heiss G, Evans GW, Chambless LE, Riley WA, et al. Carotid artery intimal-medial thickness distribution in general populations as evaluated by B-mode ultrasound. ARIC investigators. Stroke. 1993;24(9):1297–304.

16. Tzou WS, Douglas PS, Sinivasan SR, Bond MG, Tang R, Li S, et al. Distribution and predictors of carotid intima-media thickness in young adults. Prev Cardiol. 2007;10(4):181–9.

17. Sekikawa A, Ueshima H, Kadowaki T, El-Saed A, Okamura T, Takayama T, et al. Less subclinical atherosclerosis in Japanese men in Japan than in white men in the united states in the post-war World II birth cohort. Am J Epidemiol. 2007;165(6):617–24.

18. Bae JH, Kim WS, Lee MS, Kim KS, Park JB, Youn HJ, et al. The changes of individual carotid artery wall layer by aging and carotid intima-media thickness value for high risk. Cardiovasc Ther. 2016;34(6):397–403.

19. Peters SA, Grobbee DE, Bots ML. Carotid intima-media thickness: a suitable alternative for cardiovascular risk as outcome? Eur J Cardiovasc Prev Rehabil. 2011;18(2):167–74.

20. Bots ML, Hofman A, de Bruyn AM, de Jong PT, Grobbee DE. Isolated systolic hypertension and vessel wall thickness of the carotid artery. The Rotterdam elderly study. Arterioscler Thromb. 1993;13(1):64–9.

21. Knuiman M, Magnussen CG, Venn A, Dwyer T, Burns TL, Davis PH, et al. Influence of age on associations between childhood risk factors and carotid intima-media thickness in adulthood. Circulation. 2010;122(24):2514–20.

22. Juhola J, Magnussen CG, Berenson GS, Venn A, Burns TL, Sabin MA, et al. Combined effects of child and adult elevated blood pressure on subclinical atherosclerosis. Circulation. 2013;128(3):217–24.